Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

StUbEx PLUS in U2OS

ABSTRACT: StUbEx PLUS – a modified Stable tagged Ubiquitin Exchange system for Peptide Level purification and in-depth mapping of Ubiquitination Sites. Applying StUbEx PLUS to U2OS cells treated with proteasomal inhibitors MG132 or Bortezomib resulted in the identification of 41,582 sites mapping on 7,762 proteins. In addition, 72 proteins were identified with N-terminal protein ubiquitination.

INSTRUMENT(S): Q Exactive HF

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Osteosarcoma Cell Line

SUBMITTER: Iñigo Barrio

LAB HEAD: Blagoy Blagoev

PROVIDER: PXD006092 | Pride | 2022-03-01

REPOSITORIES: Pride

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	20150528LO_Qe1_0525a18r_HpH_Dox_1.raw	Raw
	20150528LO_Qe1_0525a18r_HpH_Dox_10.raw	Raw
	20150528LO_Qe1_0525a18r_HpH_Dox_11.raw	Raw
	20150528LO_Qe1_0525a18r_HpH_Dox_12.raw	Raw
	20150528LO_Qe1_0525a18r_HpH_Dox_13.raw	Raw

Items per page:

1 - 5 of 163

Publications

StUbEx PLUS-A Modified Stable Tagged Ubiquitin Exchange System for Peptide Level Purification and In-Depth Mapping of Ubiquitination Sites.

Akimov Vyacheslav V Olsen Louise C B LCB Hansen Sten V F SVF Barrio-Hernandez Inigo I Puglia Michele M Jensen Søren S SS Solov'yov Ilia A IA Kratchmarova Irina I Blagoev Blagoy B

Journal of proteome research 20171101 1

Modulation of protein activities by reversible post-translational modifications (PTMs) is a major molecular mechanism involved in the control of virtually all cellular processes. One of these PTMs is ubiquitination, which regulates key processes including protein degradation, cell cycle, DNA damage repair, and signal transduction. Because of its importance for numerous cellular functions, ubiquitination has become an intense topic of research in recent years, and proteomics tools have greatly fa ...[more]

PMID: 29091453

Similar Datasets

Analysis of transcriptional changes associated to proteasome inhibition in HCT-116 human colorectal cancer cells

Project description:The proteasome is a central player in several cellular aspects, such as homeostasis, cell cycle progression, and even transcription. Recent work has shown that proteasome inhibition promotes pervasive epigenetic changes in the human genome. However, the impact of proteasome inhibitors on ncRNAs is poorly understood. We treated control (asynchronous) or G2-synchronized HCT-116 human colon cancer cells with the proteasome inhibitors MG132 and bortezomib and performed total RNA-seq. We also included cells treated simultaneously with MG132 and the RNA-pol II inhibitor α-amanitin to determine the transcriptional changes mediated by such RNA polymerase. We report that MG132 and bortezomib impact similar regions of the genome. A remarkable transcriptional activation was observed in centromeres and pericentromers, especially in α-satellite repeats. RNAs emanating from these regions are known to participate in chromosome segregation. Our results suggest that the proteasome can regulate mitotic progression, not only by participating in protein turnover, but also by regulating ncRNAs.

2021-12-14 | GSE165325 | GEO

Transcription profiling of human MCF-7 cells treated with proteasome inhibitor MG132 and either dexamethasone or 17b-estradiol

Project description:The objective of the study was to investigate the effect of proteasome inhibition on glucocorticoid and estrogen receptor regulated gene expression. Experiment Overall Design: MCF-7 cells were treated with proteasome inhibitor (MG132), dexamethasone, 17b-estradiol or MG132 plus dexamethasone or MG132 plus 7b-estardiol. Control cells were not treated. RNA was collected from 2 biological experiments.

2008-06-20 | E-GEOD-8383 | biostudies-arrayexpress

Newcastle MSI Plus Assay

Project description:Newcastle MSI Plus Assay

| PRJEB67820 | ENA

Rapid degradation pathways of host proteins during HCMV infection revealed by quantitative proteomics

Project description:Human cytomegalovirus is an important pathogen in immunocompromised individuals and neonates, and a paradigm for viral immune evasion. We previously developed a quantitative proteomic approach that identified 133 proteins degraded during the early phase of HCMV infection, including known and novel antiviral factors. The majority were rescued from degradation by MG132, which is known to inhibit lysosomal cathepsins in addition to the proteasome. Global definition of the precise mechanisms of host protein degradation is important both to improve our understanding of viral biology, and to inform novel antiviral therapeutic strategies. We therefore developed and optimised a multiplexed comparative proteomic analysis using the selective proteasome inhibitor bortezomib in addition to MG132, to provide a global mechanistic view of protein degradation. Of proteins rescued from degradation by MG132, 62-85% were also rescued by bortezomib, suggesting both that the predominant mechanism of protein degradation employed by HCMV is via the proteasome, and that alternative pathways for degradation are nevertheless important. Our approach and data will enable improved mechanistic understanding of HCMV and other viruses, and provide a shortlist of candidate restriction factors for further analysis.

2021-01-08 | PXD021961 | Pride

Proteome Composition of Lysosomes and Autophagosomes after Proteasome Inhibition

Project description:Lysosomes are a major site of intracellular acidic hydrolase-mediated proteolysis and cellular degradation in a membrane-enclosed organelle. Alternatively, soluble, ubiquitin-bound proteins are degraded via the proteasome, a megadalton protein complex within the cytoplasm. The interplay between both degradation pathways has been of increasing interest in recent years. To determine the effects of proteasome inhibition on the lysosomal compartment, we investigated enriched lysosomal fractions, autophagosomal fractions and immunoprecipitated proteasomes from HEK293 cells after proteasome inibition by MG132 or bortezomib in comparison to the respective fractions from control cells.

2020-04-20 | PXD015243 | Pride

DIRECT PLUS 16s rRNA data

Project description:DIRECT PLUS 6-month 16s rRNA data

| PRJEB49146 | ENA

DIRECT PLUS Shotgun Metagenomics data

Project description:DIRECT PLUS 6-month Shotgun Metagenomics data

| PRJEB49147 | ENA

Transcription profiling of human cell cancer line treated with bortezomib or Eeyarestatin I (EerI) reveals ERAD inhibitors integrate ER stress with an epigenetic mechanism to activate BH3 only protein NOXA in cancer cells

Project description:The ubiquitin-proteasome system (UPS) has recently emerged as a major target for drug development in cancer therapy. The proteasome inhibitor bortezomib has clinical activity in multiple myeloma and mantle cell lymphoma. Here we report that Eeyarestatin I (EerI), a chemical inhibitor that blocks ER-associated protein degradation (ERAD), has anti-tumor and biologic activities similar to bortezomib, and can synergize with bortezomib. Like bortezomib, EerI-induced cytotoxicity requires the upregulation of the BH3 only pro-apoptotic protein NOXA. We further demonstrate that both EerI and bortezomib activate NOXA via an unanticipated mechanism that requires cooperation between two processes: First, these agents elicit an integrated stress response program at the ER to activate the CREB/ATF transcription factors ATF3 and ATF4. We show that ATF3 and ATF4 form a complex capable of binding to the NOXA promoter, which is required for NOXA activation. Second, EerI and bortezomib also block ubiquitination of histone H2A to relieve its inhibition on NOXA transcription. Our results identify a class of anti-cancer agents that integrate ER stress response with an epigenetic mechanism to induce cell death. Experiment Overall Design: 1. EerI 10 vs 0 Experiment Overall Design: 2. EerI 10 vs 0 Experiment Overall Design: 3. Bzm 10 vs 0 Experiment Overall Design: 4. Bzm 10 vs 0

2009-02-28 | E-GEOD-14003 | biostudies-arrayexpress

ERAD inhibitors integrate ER stress with an epigenetic mechanism to activate BH3 only protein NOXA in cancer cells

2009-02-20 | GSE14003 | GEO

Gene expression of RAW 264.7 cells treated with LPS, ISO, PGE2, LPS PLUS ISO, and LPS PLUS PGE2

Project description:LPS plus ISO and LPS plus PGE2 had non-additive effects on gene expression in RAW 264.7 cells Keywords: time course

2006-06-06 | GSE4964 | GEO